SAFE vs Convertible Note for Startup Financing Terms?

Conversion basics - SAFEs and convertible notes turn into equity when a qualified financing (a 'priced round') occurs. The exact number of shares you receive depends on the round's terms, any caps or discounts, and - for notes - accrued interest.

Assumptions for this section

• Priced round: an equity financing where the company sets a pre‑money valuation and issues new shares.
• Timing: conversion happens at the closing of that round, unless the instrument specifies an earlier trigger (e.g., acquisition).
• Currency: conversion is calculated in the same currency used for the investment and the financing round.

How to work out your conversion

1. Identify the trigger event - Confirm that the round meets your instrument's definition of a conversion event (usually a priced round of at least a minimum amount).
2. Find the conversion price -
   • If a valuation cap is present, divide the cap by the total fully‑diluted share count used in the round; the lower of this price and the round price applies.
   • If a discount is included, apply the discount percentage to the round price; again, the lower of cap‑price or discounted price is used.
3. Add note interest (convertible notes only) - Calculate accrued interest up to the conversion date and treat it as additional principal when applying the price from step 2.
4. Compute share quantity - Divide your principal (SAFE amount or note principal + interest) by the conversion price determined in step 2. Round according to the instrument's rounding rules, if any.
5. Check post‑conversion ownership - Add the new shares to the existing cap table, then recalculate each stakeholder's percentage to see the dilution impact.

Quick tip: Keep a spreadsheet that updates automatically when you change the round's valuation, size, or discount; it will show the resulting share count and ownership instantly.

Safety note - Terms vary by issuer and jurisdiction; verify the exact conversion mechanics in your agreement and consider a professional review before finalizing any financing.

A valuation cap tells the instrument to convert at the lower of the cap‑price or the actual round price, so it can dramatically reduce the number of shares you issue if the next round values the company above the cap.

How to calculate the conversion amount

Assumptions: Investment = $X, Cap = $C (pre‑money valuation), Next‑round pre‑money valuation = $V, Option‑pool increase (if any) = P %.

• Step 1: Determine the conversion share price.
  • If V > C, use Cap‑price = C ÷ (fully‑diluted shares before the round).
  • If V ≤ C, use Round‑price = V ÷ (fully‑diluted shares before the round).
• Step 2: Adjust for any new option pool.
  • Effective shares = (pre‑round shares + new pool × P%).
  • Divide the chosen price (cap‑price or round‑price) by this adjusted share count.
• Step 3: Compute the investor's equity.
  • Shares issued = Investment ÷ Effective conversion price.
• Step 4: Compare scenarios.
  • Repeat the calculation with the round‑price (no cap) to see the dilution difference.

What to double‑check

• The cap is expressed as a pre‑money valuation, not a per‑share price.
• Your SAFE or note's conversion clause (some include a 'most‑favored‑nation' provision that can alter the effective price).
• Whether the calculation includes the post‑money option pool, as many issuers do.

Verify the numbers against your legal counsel's model before finalizing the financing.

A discount lowers the conversion price, so the investor receives more shares for the same investment amount. For example, if a $200,000 SAFE carries a 20 % discount and the next priced round is set at $10 per share, the discounted price becomes $8 per share, giving the investor 25,000 shares instead of the 20,000 shares they would get at the full price. The extra 5,000 shares represent the 'discount‑boosted' conversion value.

Without a discount (or when a valuation cap, not a discount, governs conversion), the same $200,000 would convert at the round price of $10 per share, yielding only 20,000 shares. The investor's ownership stake is therefore lower, and the startup experiences slightly less dilution. Check your instrument's terms to see whether a discount, a cap, or the more favorable of the two applies at the trigger event, typically a qualified equity financing.

Interest accrues on a convertible note until it converts or reaches its maturity date, and both the rate and the maturity timeline can shift dilution and fundraising timing for your startup.

Notes may carry simple interest (a fixed percentage applied to the principal) or compound interest (interest added to the principal and then re‑interest‑ed). Most issuers use simple interest, typically ranging from 2% to 8% annually, but the exact rate varies by investor and market conditions. interest amount is added to the principal when the note converts, increasing the number of shares the investor receives.

Key ways interest and maturity influence your company

• Higher conversion shares - The accrued interest becomes part of the conversion price, so a larger interest balance means more equity for the investor and greater dilution for existing shareholders.
• Maturity pressure - If the note reaches its maturity date without a qualified financing, it may convert at a pre‑agreed price, trigger a mandatory repayment, or give the investor the right to demand repayment. This forces the startup to close a priced round or secure other liquidity before the deadline.
• Valuation‑cap interaction - Interest added to the principal is subject to the same valuation cap as the original note amount, potentially pushing the effective conversion price lower and amplifying dilution.
• Fundraising flexibility - Longer maturities give you more runway to hit milestones before a priced round, but they may also make later investors wary of 'old' debt on the cap table. Short maturities can speed up a financing round but increase pressure on operations.
• Accounting and cash‑flow impact - Even though interest is not paid in cash until conversion, it must be recorded as a liability, which can affect financial statements and may influence lender or investor perception.

Before signing a convertible note, verify the interest calculation method, the annual rate, and the exact maturity date. Model how the accrued interest will affect share count under different financing scenarios, and ensure the maturity timeline aligns with your product roadmap and fundraising plan. If flexibility is a priority, consider negotiating a lower rate, a longer maturity, or a 'pay‑off' provision that allows conversion without triggering mandatory repayment.

Investors compare a SAFE and a convertible note by weighing risk, potential return, contractual complexity, and timing of repayment.

• Maturity and repayment risk - A note includes a set maturity date and may require cash repayment if no equity round occurs, giving investors a fallback claim; a SAFE lacks a maturity clause, so investors must rely entirely on future equity conversion.
• Interest accrual - Convertible notes typically accrue interest that adds to the conversion amount, boosting investor upside; SAFEs do not earn interest, which can make them less attractive when the financing timeline is uncertain.
• Conversion certainty - Both instruments convert at a valuation cap or discount, but notes often have clearer trigger events (qualified financing, maturity, liquidation) that reduce ambiguity for investors.
• Documentation and legal exposure - SAFEs are shorter and simpler, lowering legal costs and potential for disputes; notes are longer contracts that may introduce more negotiation points and enforceability considerations.
• Investor liquidity expectations - Because notes can become payable debt, they may appeal to investors seeking a quicker path to cash or a senior position in liquid​ation; SAFEs are purely equity‑linked, aligning investors with long‑term upside but offering no immediate repayment option.

Pick a SAFE when you are at the seed or pre‑seed stage, need to close the round quickly, and want to keep legal fees low. SAFEs have no interest or maturity date, so they avoid the timing pressure that comes with a convertible note. If you expect a priced Series A within a year and can accept a simple valuation cap or discount as the only conversion triggers, a SAFE usually speeds fundraising and reduces negotiation friction.

Choose a SAFE instead of a convertible note if your investors are comfortable with pure equity conversion and you do not need the debt‑like protections that notes provide. This is common when you anticipate rapid growth, have a clear path to a priced round, and prefer to avoid the administrative burden of tracking accrued interest. As always, verify the specific terms in your agreement and consult legal counsel before finalizing any instrument.

Pick a convertible note when you want debt‑style features - interest that accrues until conversion, a defined maturity date, and the ability to renegotiate if the next financing stalls. These elements give both founders and investors a clearer timeline and a modest safety net compared with a SAFE, which typically has no interest or deadline.

A note's maturity creates pressure to close a priced round before it expires, which can be useful if you need to signal urgency to investors. The accrued interest also boosts the investors' eventual equity stake, often making the note more attractive to parties that prefer a modest upside rather than a pure equity‑only instrument. Additionally, many venture funds are accustomed to notes and may negotiate tighter caps or discounts because they can assess the debt component.

The trade‑off is added legal complexity and potential cash‑flow impact from interest that must be paid (or added to the conversion amount). Make sure the maturity term fits your fundraising runway and that you understand any default provisions. If you're unsure, run a quick dilution model and consult counsel before committing to a note.

Start by laying out the numbers you'll feed into the model: pre‑money valuation (or a range you expect), amount you plan to raise, the SAFE's valuation cap and discount (if any), and for a convertible note the cap, discount, interest rate, and maturity‑date accrued interest. Keep these inputs in a spreadsheet so you can tweak one variable at a time.

1. Set the conversion price for the SAFE
   • If the SAFE has a cap, conversion price = cap ÷ fully‑diluted shares before the round.
   • If it also carries a discount, use the lower of (cap price) and (discounted price = next‑round price × (1  -  discount)).
   • Record the price per share you'll apply.
2. Set the conversion price for the note
   • Start with the same cap‑price calculation as the SAFE.
   • Add accrued interest: principal × interest × ( months / 12 ).
   • Increase the principal by that interest, then apply the cap/discount rule just as for the SAFE.
   • This yields the note's effective price per share.
3. Calculate shares issued to each instrument
   • Shares = investment amount ÷ conversion price.
   • Do this separately for the SAFE and for the note using the prices from steps 1 and 2.
4. Determine post‑money ownership
   • Post‑money shares = pre‑money shares + new shares from the raise + SAFE shares + note shares.
   • Ownership % = shares issued to that instrument ÷ post‑money shares.
5. Compute dilution
   • Dilution to existing founders = 1  -  (founder post‑money shares ÷ post‑money shares).
   • Compare the dilution percentages from the SAFE‑only scenario versus the note‑only scenario.
6. Run sensitivity checks
   • Vary the pre‑money valuation, cap, discount, and interest to see how each moves the dilution curve.
   • Highlight the combination that yields the lowest founder dilution while meeting investor expectations.
7. Document assumptions
   • Note any 'as‑if' pricing (e.g., assuming the next round is priced at $X per share).
   • Keep a record of the version of the term sheet used for each run.

Double‑check the final numbers against the actual term sheets and your cap table before committing to either instrument.

Start with a proven template and a streamlined workflow to keep lawyer hours low and the round moving fast.

• Choose an off‑the‑shelf SAFE or convertible‑note template (e.g., Y Combinator's SAFE) that matches your financing stage and jurisdiction.
• Run the chosen template through a single, early review by a qualified attorney; a brief, focused pass reduces the need for multiple revisions.
• Limit the number of distinct terms per round (e.g., one cap, one discount) so the same legal language applies to all investors.
• Use an electronic signature platform that complies with e‑sign regulations to eliminate physical paperwork and accelerate closing.
• Consolidate investor due‑diligence requests into a single data‑room; a well‑organized folder cuts back‑and‑forth questions.
• Set a firm internal deadline for term finalization and share it with investors; clear timelines keep counsel and founders aligned.
• Leverage cap‑table software to automatically calculate dilution scenarios; accurate models reduce back‑and‑forth with lawyers.

(Keep in mind that template suitability and e‑sign compliance can vary by state, so verify those details before finalizing.)

combined conversion math can push dilution higher than each instrument would cause on its own.

Consider a financing round priced at $10 M post‑money and three outstanding instruments as an illustration (assumes the same round price for all):

• SAFE with a $4 M cap,
• SAFE that offers a 20 % discount,
• convertible note with a $5 M cap that has accrued interest of roughly 8 % (typical for early‑stage notes).

When the round closes, the cap‑based SAFE converts at the lower $4 M price, the discount SAFE converts at 80 % of the $10 M price, and the note converts at its $5 M cap plus the accrued interest, effectively adding another 8 % of shares. total number of shares issued can be substantially larger than the sum of the individual percentages - often a 10 %‑20 % increase in dilution compared with a single instrument.

prevent surprise dilution, 

• model every instrument against the same financing price,
• identify which cap or discount yields the most shares for each investor,
• check for 'most‑favored‑nation' (MFN) clauses that could cause later instruments to adopt the most aggressive terms,
• confirm interest rates and maturity dates on notes, since accrued interest adds shares at conversion, and
• consider consolidating caps or negotiating a ceiling on total dilution before closing the round.

Running a simple spreadsheet with these inputs lets you see the worst‑case share count and negotiate terms that keep dilution within a comfortable range. Always verify the exact language in each term sheet before signing.

If you never raise a priced round, the SAFE or convertible note generally stays unconverted.

For a convertible note, the maturity date usually triggers repayment of the principal (and any accrued interest) if conversion has not occurred. Some issuers negotiate extensions, but without a priced round the default obligation is to repay the loan, which can strain cash flow or force a renegotiated conversion at a later event.

A SAFE does not have a maturity date, so it can remain outstanding indefinitely. In practice, investors may push for a conversion at a liquidity event such as an acquisition, or they may seek to amend the agreement to include a repayment provision. Until then, the SAFE sits on the cap table as a potential dilution source, and the company must disclose it to future investors.

Both instruments can affect future fundraising: investors will scrutinize the amount of uncapped SAFEs or notes awaiting conversion, and they may demand lower caps or higher discounts to compensate for the uncertainty. Keep track of all outstanding SAFEs and notes, model worst‑case dilution, and be prepared to discuss repayment or conversion options before you approach new investors.